<DOC>
	<DOCNO>NCT00675012</DOCNO>
	<brief_summary>The main objective trial document safety NGR-hTNF administer low high dos combination standard oxaliplatin base regimen patient metastatic colorectal cancer amenable clinical improvement current standard treatment</brief_summary>
	<brief_title>NGR-hTNF Administered Combination With Standard Oxaliplatin Based Regimen Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Phase II , open-label , non-randomized study conduct two sequential cohort patient . Patients metastatic colorectal cancer amenable clinical improvement current standard treatment plan enrol .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients ≥ 18 year metastatic colorectal cancer ( CRC ) treat three standard systemic regimen ( include biologic agent ) metastatic disease Life expectancy 3 month ECOG Performance status 01 Adequate baseline bone marrow , hepatic renal function , define follow : Neutrophils &gt; 1.5 x 10^9/L platelet &gt; 100 x 10^9/L Bilirubin &lt; 1.5 x ULN AST and/or ALT &lt; 2.5 x ULN absence liver metastasis AST and/or ALT &lt; 5 x ULN presence liver metastasis Serum creatinine &lt; 1.5 x ULN Creatinine clearance ( estimate accord CockcroftGault formula ) ≥ 50 ml/min Patients may prior therapy provide follow condition meet : Chemotherapy , radiation therapy , hormonal therapy immunotherapy : washout period 28 day start treatment Surgery : washout period 14 day start treatment Patients must give write informed consent participate study Concurrent anticancer therapy Patients must receive investigational agent study Patients myocardial infarction within last six ( 6 ) month , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication Uncontrolled hypertension Prolonged QTc interval ( congenital acquire ) Patient significant peripheral vascular disease Clinical sign CNS involvement Patients active uncontrolled systemic disease/infections serious illness medical condition , incompatible protocol Symptomatic peripheral neuropathy ≥ grade 1 accord NCI CTCAE v.3.0 . Known hypersensitivity/allergic reaction contraindication human albumin preparation excipients Known hypersensitivity/allergic reaction contraindication platinum compound fluoropyrimidines Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol Pregnancy lactation . Patients male female reproductive potential ( i.e . menopausal le 1year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>NGR-hTNF</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Colon cancer</keyword>
</DOC>